Trial Profile
Phase II Study of Apatinib Mesylate Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Sep 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenoid cystic carcinoma; Head and neck cancer
- Focus Therapeutic Use
- 24 Sep 2018 Planned End Date changed from 1 May 2018 to 1 Dec 2018.
- 05 Jun 2018 Between Apr 2016 and Dec 2017, 59 patients were recruited, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Results evaluating the efficacy and safety of Apatinib Mesylate were presented at the 54th Annual Meeting of the American Society of Clinical Oncology